Year: 2023

SeagenAstellas_1

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival...

CL_logo_28129-2

CyberLink FaceMe® Security Integrates with Genetec Security Center to Enhance Investigations and Secure Access Control with AI Facial Recognition

TAIPEI, Taiwan--(BUSINESS WIRE)--CyberLink Corp. (5203.TW), a pioneer in AI and facial recognition technology, today announces FaceMe® Security certified integration with...

logo-65

Global Cardiology IT Workflow Solutions Research Report 2023: Market to Reach $1.8 Billion by 2030 – Artificial Intelligence (AI) to Revolutionize Cardiology Workflow Management – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cardiology IT Workflow Solutions - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Cardiology IT...